Exclusive Summary

• Levofloxacin ophthalmic solution's original patent has long expired, creating a mature generic market where Chinese suppliers with global compliance and cost advantages are ideal partners.
• With a vast and growing global patient base for bacterial eye infections, Levofloxacin, an essential WHO medicine and guideline-recommended first-line treatment, ensures stable market demand.
• Positioned as a broad-spectrum, effective anti-infective eye drop, it offers a high-quality, cost-effective solution to penetrate existing sales channels in a competitive generic market.
• Matching with customers experienced in registration or with strong distribution networks in target countries facilitates rapid market entry and sales for the product.
• Chinese manufacturers' strong production capabilities and international compliance experience provide robust support to overseas pharmaceutical companies seeking diversified, cost-effective, and quality-assured supply.